US Patent Issued to BEIJING IMMUNOCHINA PHARMACEUTICALS on Jan. 20 for "Optimization of chimeric antigen receptor" (Chinese Inventors)

ALEXANDRIA, Va., Jan. 20 -- United States Patent no. 12,528,854, issued on Jan. 20, was assigned to BEIJING IMMUNOCHINA PHARMACEUTICALS Co. LTD. (Beijing).

"Optimization of chimeric antigen receptor" was invented by Feifei Qi (Beijing), Ting He (Beijing), Xinan Lu (Beijing), Yanping Ding (Beijing), Fuyin Xiong (Beijing) and Mengmeng Liang (Beijing).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to the optimization of a chimeric antigen receptor, in particular, the modification of an intracellular signaling domain."

The patent was filed on Feb. 9, 2021, under Application No. 17/799,492.

*For further information, including images, charts and tables, please visit: http://patft.usp...